Innvervace develops regenerative therapy solutions for neurodegenerative disorders.
Innervace has raised $40.0M in total funding. The most recent round was Series A. The last funding was announced in September 2022.
Innervace's investors include BioAdvance, Deerfield, IP Group, WARF Ventures, Penn Medicine Co-Investment Program.
Innervace is headquartered in Philadelphia, United States.
Innvervace develops regenerative therapy solutions for neurodegenerative disorders.
Innervace is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Innervace — Funding & Investors." VCBacked, September 8, 2022, https://www.vcbacked.co/company/innervace. Accessed September 30, 2026.
VCBacked. (2022). Innervace — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/innervace
{{cite web |title=Innervace — Funding & Investors |url=https://www.vcbacked.co/company/innervace |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated